ClinicalTrials.gg
CompletedNCT04164199Updated Jun 3, 2026

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

A Phase 3 interventional study of Tislelizumab and Pamiparib in Advanced Malignancies, sponsored by BeOne Medicines. Completed at 106 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by BeOne Medicines · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
404
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).

Read the detailed description

For the purposes of this study, "study treatment" will refer to all investigational agents. A parent study is defined as the original BeiGene- or BeOne-sponsored clinical trial in which the participant was initially enrolled and received BeiGene or BeOne investigational drugs (with or without other treatments).

Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

02

Conditions studied

  • Advanced Malignancies
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Currently participating in a BeiGene- or BeOne-sponsored eligible parent study
  2. Fulfills treatment criteria specified in the parent study protocol
  3. In the opinion of the investigator, the participant will continue to benefit from and tolerate any of the parent study treatments.
  4. The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study:

    1. "Treatment interruption" is an unplanned pause in study treatment (eg, due to adverse event). Restarting study treatment beyond the interruption period allowed by the parent study will be determined by the investigator and the sponsor.

Key Exclusion Criteria:

  1. Permanently discontinued from all drugs in the parent study due to unacceptable toxicity, noncompliance with study procedures, or withdrawal of consent
  2. Have uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy prior to the start of the extension study
  3. Have a medical condition or organ system dysfunction that in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of investigational drugs, or put the study outcomes at undue risk
  4. Underwent treatment with any systemic anticancer treatment (other than treatment permitted in the parent study) during the time between the last treatment in the parent study and the first dose of study treatment in the LTE study
  5. Pregnant or lactating women

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
404 participants (actual)

Study arms

  • Experimental
    A - Tislelizumab Monotherapy

    Drug: Tislelizumab

  • Experimental
    B - Pamiparib Monotherapy

    Drug: Pamiparib

  • Experimental
    C - Sitravatinib Monotherapy

    Drug: Sitravatinib

  • Experimental
    D - BGB-15025 Monotherapy

    Drug: BGB-15025

  • Experimental
    E - Zanidatamab Monotherapy

    Drug: Zanidatamab

  • Experimental
    F - Pamiparib and Temozolomide Combination Therapy

    Drug: Pamiparib · Drug: Temozolomide

  • Experimental
    G - Tislelizumab and Pamiparib Combination Therapy

    Drug: Tislelizumab · Drug: Pamiparib

  • Experimental
    H - Tislelizumab and Sitravatinib Combination Therapy

    Drug: Tislelizumab · Drug: Sitravatinib

  • Experimental
    I - Tislelizumab and Ociperlimab Combination Therapy

    Drug: Tislelizumab · Drug: Ociperlimab

  • Experimental
    J - Tislelizumab and BAT1706 Combination Therapy, or BAT1706 Monotherapy

    Drug: Tislelizumab · Drug: BAT1706

  • Experimental
    K - Tislelizumab and Fruquintinib Combination Therapy

    Drug: Tislelizumab · Drug: Fruquintinib

  • Experimental
    L - Tislelizumab and BGB-A445 Combination Therapy

    Drug: Tislelizumab · Drug: BGB-A445

  • Experimental
    M - Tislelizumab and Surzebiclimab Combination Therapy

    Drug: Tislelizumab · Drug: Surzebiclimab

  • Experimental
    N - Tislelizumab and BGB-15025 Combination Therapy

    Drug: Tislelizumab · Drug: BGB-15025

  • Experimental
    O - Tislelizumab and Lenvatinib Combination Therapy

    Drug: Tislelizumab · Drug: Lenvatinib

  • Experimental
    P - Tislelizumab and Zanidatamab Combination Therapy

    Drug: Tislelizumab · Drug: Zanidatamab

  • Experimental
    Q - Tislelizumab and LBL-007 Combination Therapy

    Drug: Tislelizumab · Drug: LBL-007

  • Experimental
    R - Tislelizumab and Surzebiclimab and LBL-007 Combination Therapy

    Drug: Tislelizumab · Drug: Surzebiclimab · Drug: LBL-007

Interventions

  • Administered intravenously.

    Also known as: BGB-A317

  • Administered orally.

    Also known as: BGB-290

  • Administered orally.

  • Administered orally.

  • Administered intravenously.

    Also known as: BGB-A1217

  • Administered intravenously.

  • Administered orally.

  • DrugBGB-15025

    Administered orally.

  • Administered intravenously.

    Also known as: ZW25

  • DrugBGB-A445

    Administered intravenously.

    Also known as: Gimistotug

  • DrugSurzebiclimab

    Administered intravenously.

    Also known as: BGB-A425

  • Administered orally.

  • Administered intravenously.

    Also known as: Alcestobart

06

What researchers measure

Primary outcomes

  1. Number of Participants with Immune-Mediated Adverse Events, Serious Adverse Events, and Adverse Events Grade 3 or Higher

    Safety as assessed by the number of participants with immune-mediated adverse events (imAEs), ≥ Grade 3 adverse events, and serious adverse events.

    Time frame: up to 7 years

07

Study locations

106 sites
  • Mount Sinai Medical Center Braman Comprehensive Cancer Center
    Miami, Florida 33140, United States
  • Memorial Sloan Kettering Cancer Center Mskcc
    New York, New York 10065-6800, United States
  • Tennessee Oncology, Pllc Nashville
    Nashville, Tennessee 37203, United States
  • Baylor Research Institute
    Dallas, Texas 75246-2079, United States
  • Prince of Wales Hospital
    Randwick, New South Wales NSW 2031, Australia
  • Northern Cancer Institute
    St Leonards, New South Wales NSW 2065, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales NSW 2298, Australia
  • Icon Cancer Centre South Brisbane
    South Brisbane, Queensland QLD 4101, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia SA 5011, Australia
  • Monash Health
    Clayton, Victoria VIC 3168, Australia
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria VIC 3000, Australia
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • The Affiliated Hospital of Military Medical Sciences
    Beijing, Beijing Municipality 100071, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)
    Guangzhou, Guangdong 510000, China
  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
    Guangzhou, Guangdong 510245, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • The Fifth Affiliated Hospital Sun Yat Sen University
    Zhuhai, Guangdong 519000, China
  • The Peoples Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The Second Affiliated Hospital of Zunyi Medical University
    Zuiyi, Guizhou 550002, China
  • Hainan Cancer Hospital
    Haikou, Hainan 570312, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Zhongnan Hospital of Wuhan University Wuhan
    Wuhan, Hubei 430071, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • The First Peoples Hospital of Changzhou
    Changzhou, Jiangsu 213000, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Weifang Peoples Hospital
    Weifang, Shandong 261000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200000, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality 200030, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200092, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • West China Second University Hospital, Sichuan University
    Chengdu, Sichuan 610101, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin Municipality 300020, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830000, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • The First Provincial Wenzhou Hospital of Zhejiang
    Wenzhou, Zhejiang 325000, China
  • Hopital Beaujon
    Clichy, 92110, France
  • Hopital Prive Jean Mermoz
    Lyon, 69008, France
  • Icm Val Daurelle
    Montpellier, 34090, France
  • Centre Hospitalier Universitaire Nantes Hotel Dieu
    Nantes, 44000, France
  • Hopital Larchet 2 Chu Nice
    Nice, 06200, France
  • Policlinico Sorsola Malpighi, Aou Di Bologna
    Bologna, 40138, Italy
  • Aou Pisana, Stabilimento Di Santa Chiara
    Pisa, 56126, Italy
  • Azienda Ospedaliera S Maria Di Terni
    Terni, 05100, Italy
  • Akita University Hospital
    Akitashi, Akita 010-8543, Japan
  • Chiba Cancer Center
    Chiba, Chiba 260-8717, Japan
  • Nho Kyushu Cancer Center
    Fukuoka, Fukuoka 811-1395, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Izumi City General Hospital
    Izumishi, Osaka 594-0073, Japan
  • The University of Osaka Hospital
    Suitashi, Osaka 565-0871, Japan
  • National Cancer Center Hospital
    ChuoKu, Tokyo 104-0045, Japan
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Sarawak General Hospital
    Kuching, 93586, Malaysia
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
    Gdynia, 81-519, Poland
  • Narodowy Instytut Onkologii Im Marii Sklodowskiej Curie W Warszawie
    Warsaw, 02-781, Poland
  • Cha Bundang Medical Center, Cha University
    BundangGu SeongnamSi, Gyeonggi-do 13496, South Korea
  • National Cancer Center (Korea)
    IlsandongGu GoyangSi, Gyeonggi-do 10408, South Korea
  • The Catholic University of Korea, St Vincents Hospital
    PaldalGu SuwonSi, Gyeonggi-do 16247, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Gachon University Gil Medical Center
    NamdongGu, Incheon Gwang'yeogsi 21565, South Korea
  • Chonnam National University Hwasun Hospital
    HwasunGun, Jeollanam-do 58128, South Korea
  • Smg Snu Boramae Medical Center
    DongjakGu, Seoul Teugbyeolsi 07061, South Korea
  • Samsung Medical Center
    GangnamGu, Seoul Teugbyeolsi 06351, South Korea
  • Korea University Guro Hospital
    GuroGu, Seoul Teugbyeolsi 08308, South Korea
  • The Catholic University of Korea, Seoul St Marys Hospital
    SeochoGu, Seoul Teugbyeolsi 06591, South Korea
  • Severance Hospital Yonsei University Health System
    SeodaemunGu, Seoul Teugbyeolsi 03722, South Korea
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi 03080, South Korea
  • Asan Medical Center
    SongpaGu, Seoul Teugbyeolsi 05505, South Korea
  • Ajou University Hospital
    Suwon, 16499, South Korea
  • Chiayi Chang Gung Memorial Hospital
    Chiayi City, 61363, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Guishan Dist, 33305, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Niaosong Dist, 83301, Taiwan
  • National Cheng Kung University Hospital
    North Dist, 704, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan

Showing the first 100 of 106 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in May 2026, 77 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 15, 2019
StartActual
Dec 19, 2019
Primary completionActual
May 23, 2026
CompletionActual
May 23, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04164199
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Nov 15, 2019
Start date
Dec 19, 2019
Primary completion
May 23, 2026
Completion
May 23, 2026
Last update
Jun 3, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Pamiparib · Sitravatinib · Zanidatamab

Start the discussion